1. Introduction {#sec1-diagnostics-10-00288}
===============

Point-of-care testing (POCT) devices are diagnostic tools for rapid in-field analysis. They should be simple and accessible to unskilled operators at decentralized settings. They can be classified into several categories such as cell phone-based technologies, paper-based diagnostics tools and lab-on-a-chip-based platforms \[[@B1-diagnostics-10-00288]\]. The blood glucose meter and the pregnancy test are the most popular examples of this technology \[[@B2-diagnostics-10-00288]\]. In the last decade, research works have focused on improving sensitivity, quantification and multiplexing \[[@B3-diagnostics-10-00288]\]. Thus, POCT procedures may be applied in a variety of fields such as clinical diagnosis \[[@B4-diagnostics-10-00288]\], safety \[[@B5-diagnostics-10-00288]\], agriculture \[[@B6-diagnostics-10-00288]\], veterinary \[[@B7-diagnostics-10-00288]\], drugs \[[@B8-diagnostics-10-00288]\] and contaminants \[[@B9-diagnostics-10-00288]\].

Lateral flow immunoassays (LFIA) are widely used as POCT due to their rapidity, simplicity, and low cost. This principle combines a chromatographic system with immunochemical reactions for specific and sensitive detection. Traditionally, LFIAs have been used only as qualitative screening tests, with a visual signal for positive/negative test. The outbreak of the coronavirus disease (COVID-19) is the most recent example of the relevance of these devices in rapid screening and monitoring \[[@B10-diagnostics-10-00288]\].

The test consists of four components: sample pad, conjugate pad, nitrocellulose membrane and absorbent pad. All these parts are assembled onto a plastic card to enable the flow and get robustness. The most critical component is the nitrocellulose membrane, where the recognition elements such as antibodies, antigens or nucleotides are immobilized by means of a dispenser. The fluid test sample flows by capillarity, which means that there is no need to use pumps that require energy to run.

Different formats may be adopted in LFIA, with the sandwich format being the most common. In this assay the labelled antibody (detection antibody) forms a complex with the target analyte. These complexes will be captured at the test lines by the capture antibody immobilised on the membrane ([Figure 1](#diagnostics-10-00288-f001){ref-type="fig"}A). For low molecular weight molecules (e.g., haptens) the competitive format is used, where the absence of signal in the test line indicates the presence of the analyte ([Figure 1](#diagnostics-10-00288-f001){ref-type="fig"}B).

Nanoparticles play an important role as labels for the development of LFIA \[[@B11-diagnostics-10-00288]\]. Gold nanoparticles (AuNPs) are the most popular labelling system in qualitative analysis. They display an intense red colour due to their localized surface plasmon resonance effects \[[@B12-diagnostics-10-00288]\]. Latex nanoparticles are also widely employed in commercial LFIA due to their low cost \[[@B13-diagnostics-10-00288]\]. They provide good performance, but the detection is not as sensitive as those achieved with other systems. Moreover, the low versatility of the latex nanoparticles prevents the development of further strategies to couple the strips to transducers.

There is a recent interest on quantitative LFIA, with the aim of achieving rapid, cheap and simple tests for biomedical or environmental applications. Limitations such as sensitivity and quantification could be overcome by the use of novel nanoparticle labels. Several nanomaterials have been used for optical, electrochemical and other emerging detection principles such as magnetic systems \[[@B11-diagnostics-10-00288]\]. Fluorescent nanoparticles, which include quantum dots \[[@B14-diagnostics-10-00288]\] and up-converting phosphor technologies reporter particles \[[@B15-diagnostics-10-00288]\], are suitable tags to be detected by optical methods. Carbon nanoparticles \[[@B16-diagnostics-10-00288]\] or nanotubes \[[@B17-diagnostics-10-00288]\] have also been used with the same purpose. Colloidal selenium \[[@B18-diagnostics-10-00288]\], magnetic \[[@B19-diagnostics-10-00288]\], silver \[[@B20-diagnostics-10-00288]\], Au\@Ag core shell \[[@B21-diagnostics-10-00288]\] and platinum nanoparticles \[[@B22-diagnostics-10-00288]\] have been employed to improve the performance of the most traditional optical nanoparticles. Liposomes are promising multilabel systems through the encapsulation of dyes, thus enhance the sensitivity \[[@B23-diagnostics-10-00288]\].

Magnetic nanoparticles (MNP) are key players for the development of a new generation of biosensors based on LFIA. On one hand, they could be used for quantitative measurements provided that they are coupled with an external reader. On the other hand, enable IMS as well \[[@B24-diagnostics-10-00288]\], which improves selectivity and sensitivity. To achieve this, MNP have to be functionalized with an active biomolecule which recognizes specifically the analyte of interest. Then, these MNP bioconjugates could be used to bind the analyte and separate it from diluted samples by applying an external magnetic field (a simple magnet could be used for many applications). The analyte-MNP complexes can be subsequently transferred to another solution and concentrated in less volume \[[@B25-diagnostics-10-00288]\] as demonstrated in [Figure 2](#diagnostics-10-00288-f002){ref-type="fig"}.

Magnetic LFIA, or magnetic immunochromatographic assays, have been developed in different fields of interest. Despite their promising features, they have not yet been transferred to commercial in-vitro tests. In addition, review papers in this field are still scarce at the literature, probably due to the difficulties inherent to interdisciplinary research. The following sections provide a thorough analysis of the use of magnetic nanoparticles (MNP) in LFIA and their recent applications. We have firstly analysed the type of MNP and their features related to the transducers systems. Then the magnetic principles used at research and commercial devices are described, followed by a collection of the main applications of magnetic LFIA. This work aims to have an impact on the development of novel POCT biosensors based on magnetic LFIA.

2. Magnetic Nanoparticles as Labels in LFIA {#sec2-diagnostics-10-00288}
===========================================

The desired final properties of MNP vary depending on the synthesis routes employed. Synthesis protocols may be classified into three mains groups: chemical, physical and biological \[[@B26-diagnostics-10-00288]\]. Chemical synthesis represents 90% of total. The main chemical routes include: coprecipitation, thermal decomposition, hydrothermal, sol-gel, polyol and microemulsion methods. Chemical synthesis can be non-aqueous or aqueous \[[@B26-diagnostics-10-00288],[@B27-diagnostics-10-00288]\], the latter being more suitable for subsequent bioconjugation since the bioreagents have to be dispersed in water. In fact, the synthesis procedures are known to affect the outcome of the bioconjugation process, as reviewed elsewhere \[[@B28-diagnostics-10-00288]\]. Once MNP are prepared, characterization of their physicochemical properties is an essential step for their control and quality \[[@B27-diagnostics-10-00288],[@B28-diagnostics-10-00288]\]. The main parameters are shown in [Table 1](#diagnostics-10-00288-t001){ref-type="table"}.

In order to use MNPs as label in immunoassays, they need to be stabilized with chemical compounds holding a functional group for covalent reaction with active biomolecules (antibodies, aptamers, nucleic acids). In contrast to gold nanoparticles, the attachment of the biorecognition elements to MNPs by passive adsorption is not feasible. Various coating chemistries are therefore required for bioconjugation. The surface functional groups are a critical parameter that determines the chemical reactions and enables a proper functionalization \[[@B29-diagnostics-10-00288]\]. Carboxyl-functionalized MNPs are widely used, since they easily bind the amino groups on bioreceptors and form covalent bonds by using the EDC-NHS (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/*N*-hydroxysuccinimide) chemistry. Other approach involves the coating of MNP with gold nanoparticles. These can be directly attached to biological molecules due to hydrophobic attractions, ionic interactions and dative binding \[[@B30-diagnostics-10-00288]\]. The magnetic nanoparticles used for lateral flow immunoassay in the literature vary in size (10--400 nm), type of chemical coating and crystal phases. Coatings can be classified into two broad groups depending on their chemical nature: organic and inorganic \[[@B31-diagnostics-10-00288]\]. These surface layers include hydroxyl, carbohydrate, thiol and phosphonate groups \[[@B26-diagnostics-10-00288]\]. Magnetite and maghemite are the preferred crystal structures due to their good magnetic response, biocompatibility, facile synthesis and low-cost production \[[@B32-diagnostics-10-00288]\]. The magnetic nanoparticles for LFIA are usually spherical. [Figure 3](#diagnostics-10-00288-f003){ref-type="fig"} shows an example of magnetite nanoparticles. [Figure 3](#diagnostics-10-00288-f003){ref-type="fig"}A shows dispersed nanoparticles with a perfect spherical morphology, whereas [Figure 3](#diagnostics-10-00288-f003){ref-type="fig"}B shows polydisperse nanoparticle aggregates with an irregular spherical shape.

The optimal type of magnetic nanoparticles depends on the final applications and the magnetic transducing principle. The different parameter related to MNP (size, crystallinity, dispersity, magnetic properties and coating) can be controlled by the synthesis procedure.

In recent years, the interest for the use of nanocomposites or core/shell nanoparticles has increased significantly. This kind of nanocomposites could synergistically combine the advantages of both nanoparticles \[[@B33-diagnostics-10-00288]\]. Fe~3~O~4~/Au core/shell nanoparticles have been used in lateral flow immunoassay to improve the sensitivity of the assay. Gold nanoparticles can be attached to biomolecules directly, and the test line shows intense red colour. In addition, the magnetic core allows easy separation using a magnet. For this reason, Fe~3~O~4~/Au core/shell nanoparticles have been widely reported in lateral flow immunoassay as label to detect different analytes \[[@B34-diagnostics-10-00288],[@B35-diagnostics-10-00288],[@B36-diagnostics-10-00288],[@B37-diagnostics-10-00288]\].

[Figure 4](#diagnostics-10-00288-f004){ref-type="fig"} shows a scheme of core/shell nanoparticles and different strategies to conjugate biorecognition elements. Gold nanoparticles are attached directly to proteins through i) hydrophobic attractions between the protein and the metal surface, ii) ionic interactions between the negatively charged nanoparticle and the positively charged sites on the protein and iii) dative binding between the metal and the conducting electrons of nitrogen and sulphur atoms of the protein ([Figure 4](#diagnostics-10-00288-f004){ref-type="fig"}A) \[[@B38-diagnostics-10-00288]\]. In addition, gold coating could be modified with functional groups (such as hydroxyl, amine or carboxyl) to establish a covalent bond with proteins. In this case, functional groups have to be activated on the nanoparticle surface in order to attach biomolecules ([Figure 4](#diagnostics-10-00288-f004){ref-type="fig"}B). In contrast, MNPs have to be modified with functional groups first to enable the binding of the proteins to the particle ([Figure 4](#diagnostics-10-00288-f004){ref-type="fig"}C).

3. Detection of Magnetic Nanoparticles Used as Labels in LFIA {#sec3-diagnostics-10-00288}
=============================================================

3.1. Optical Transduction {#sec3dot1-diagnostics-10-00288}
-------------------------

Magnetic nanoparticles can be detected at the test line in LFIA by means of optical techniques ([Figure 5](#diagnostics-10-00288-f005){ref-type="fig"}). MNP have a molar absorption coefficient comparable with colloidal gold in the visible range \[[@B19-diagnostics-10-00288]\]. For this reason, the magnetic nanoparticles are used as colorimetric labels in lateral flow immunoassays, showing a dark brown colour easily distinguishable on white nitrocellulose membranes. The optical density signal displayed by magnetic nanoparticles can be observed by naked eye ([Figure 5](#diagnostics-10-00288-f005){ref-type="fig"}A) or by the use of optical commercial readers and smartphones \[[@B39-diagnostics-10-00288]\]. Magnetic nanoparticles aggregates have been used in order to decrease the detection limit thanks to the controlled agglomeration with poly-L-lysine \[[@B19-diagnostics-10-00288]\]. The limit of detection achieved for aggregates is almost 40-fold lower than the values achieved with single dispersed magnetic nanoparticles. Yan et al. \[[@B40-diagnostics-10-00288]\] have reported other advantageous strategy to enhance the optical signal (reflectance) based on the generation of magnetic network complex by means of secondary antibodies.

Mobile phones and home-scanners have been integrated to LFIA as decentralized diagnostic tools ([Figure 5](#diagnostics-10-00288-f005){ref-type="fig"}B). Their simplicity and affordability make them not only a perfect candidate for devices in developing countries \[[@B41-diagnostics-10-00288]\], but also an easy-to-use tool for patients requiring regular controls that may eventually reduce costs to the National Health systems. Moreover, some manufacturers provide special software, such as Novarum© or Halomic© to process strips. Applications for phone devices can provide analytical parameters for rapid tests and in simple way even in field conditions \[[@B42-diagnostics-10-00288]\]. Several approaches have been reported in order to improve the limits of detection \[[@B43-diagnostics-10-00288],[@B44-diagnostics-10-00288]\]. Ruppert et al. \[[@B43-diagnostics-10-00288]\] have designed a statistical software which includes the colorimetric readout of test strip and tools for background and baseline correction. Saisin et al. \[[@B44-diagnostics-10-00288]\] have optimized the camera exposure time in order to improve the sensitivity and limit of detection. They achieved enhancements up to 3-fold and 5-fold, respectively. In addition, numerous optical readers have been commercialized by several companies: Detekt Biomedical (Austin, TX, USA), Qiagen (Hilden, Germany), Axxin Inc. (Fairfield, Australia), LRE medical (Nordlingen, Germany), Abbott (Libertyville, IL, USA), Optricon (Berlin, Germany), Skannex (Oslo, Norway) and BD Company (Franklin Lakes, NJ, USA).

3.2. Magnetic Transduction {#sec3dot2-diagnostics-10-00288}
--------------------------

Magnetic detection offers several advantages over optical detection. Optical detectors only record the intensity of colour from the top layer of the membrane. However, magnetic detectors can quantify the magnetic nanoparticles within the full thickness of the membrane. In addition, the magnetic signals are stable for longer time than optical signals, and magnetic nanoparticles can be used to preconcentrate the analyte of interest.

Up to now, several methods to quantify magnetic nanoparticles at the detection zones in LFIA have been described in the literature. They are based on different physicochemical transducing principles which can be divided into two groups: magnetoresistive readers and inductive readers. Some of them are commercially available and others have been developed by academic research groups with the aim of improving the analytical characteristics or portability requirements. The different types of nanoparticles used for each transducing principle are shown in [Table 1](#diagnostics-10-00288-t001){ref-type="table"}. In order to select the optimal nanoparticles, several parameters must be taken into account. The size depends on the specific applications and the transducing principle, as shown in [Table 2](#diagnostics-10-00288-t002){ref-type="table"}. EDC-NHS chemistry was used for bioconjugation in all the cited works.

### 3.2.1. Magnetoresistive LFIA Readers {#sec3dot2dot1-diagnostics-10-00288}

Magnetoresistance (MR) is the dependence of the electrical resistivity on the applied magnetic field. Sensors based on this principle have been adapted to the dimensions of LFIA to detect the stray field fringes that the magnetic labels produce \[[@B45-diagnostics-10-00288]\]. After calibration, the change in the sensor electrical resistance provides a measure of the number of particles, and consequently, the number of analytes immobilized at the strip test or control line.

Magnetoresistive sensors for biodetection are based on Giant MR (GMR) or Tunnel MR (TMR). GMR and TMR devices have an underlying common structure, namely, two ferromagnetic metal films separated by a non-magnetic film. The difference between the structures of these devices is in the non-magnetic spacer, which can be conductive (GMR) or insulating (TMR) ([Figure 6](#diagnostics-10-00288-f006){ref-type="fig"}A) \[[@B52-diagnostics-10-00288]\]. The electrical resistance depends on the relative angle between the magnetization of the two ferromagnetic layers. When they are magnetized parallel, the resistance is small, and it increases for antiparallel alignment.

In GMR, the multilayers can be engineered to have parallel/antiparallel alignment in the absence of field so that the resistance is low/high \[[@B66-diagnostics-10-00288]\]. Frequently, one of the layers has a pinned or fixed magnetization (meaning that it is hard to revert, either because it is a hard ferromagnet, a field-cooled antiferromagnet or because it is magnetically pinned by an additional layer.) Then, the applied field tends to modify the magnetization of the free layer, so modifying the resistance (see the black line in the graph of [Figure 6](#diagnostics-10-00288-f006){ref-type="fig"}B). Typically, the relative change of resistance is on the order of 5--10%. There are different types of GMR structures, depending on the non-magnetic conducting spacer and the type of magnetic layers, such as antiferromagnetic superlattices, spin valves or pseudo-spin valves.

Some research groups have developed models adapted of GMR sensors for magnetic LFIA that show an excellent potential sensitivity and spatial resolution \[[@B45-diagnostics-10-00288],[@B46-diagnostics-10-00288]\]. The basic idea of this detection is schematized in [Figure 6](#diagnostics-10-00288-f006){ref-type="fig"}B: When the LFIA is placed on top of the free layer of the sensor, and the magnetic nanoreporters are magnetized by the applied field, they produce below a magnetostatic field (whose field lines are represented by dashed grey lines) that effectively decreases the magnetic field in the free layer. In consequence, the MR response in the presence of the LFIA is given by the red line in [Figure 6](#diagnostics-10-00288-f006){ref-type="fig"}B. Taton et al. \[[@B47-diagnostics-10-00288]\] achieved detection of only 12 pg/mL of interferon gamma (IFNγ), a result that is comparable to enzyme-linked immunosorbent assays (ELISA). Serrate et al. \[[@B48-diagnostics-10-00288]\] have reported a limit of detection for human chorionic gonadotropin hormone that is below the visual inspection limit (5.5 ng/mL). Ryu et al. \[[@B49-diagnostics-10-00288]\] detected down to 0.01 ng/mL of the cardiac biomarker troponin I by reading out magnetic LFIA with a GMR sensor. Chicharro et al. \[[@B50-diagnostics-10-00288]\] have developed a novel technique and detection architecture that include spin valves sensors, which present high sensitivity to the localized magnetic field in a single direction. It allows real-time measurements of flowing nanoparticles along the membrane, and can be used for dynamic quantification of analytes flowing through lateral flow strips \[[@B51-diagnostics-10-00288]\].

In TMR (or magnetic tunnel junction MTJ) structures, the non-magnetic spacer is an electrical insulator, so thin that the electrons can tunnel through it. The tunnel crossing is more probable when both magnetizations are parallel. Then, also in this case, the applied field that produces alignment reduces the resistance. The magnetoresistance in TMR can be 5--10 times that of GMR, and the temperature drift and aging are smaller. Although they can be more sensitive, the Flicker noise coming from resistance fluctuations in TMR sensors can be larger. The literature of TMR application to LFIA reading is still scarce. Nevertheless, Lei et al. \[[@B52-diagnostics-10-00288]\] have reported promising results on human chorionic gonadotropin hormone quantification.

### 3.2.2. Inductive Readers {#sec3dot2dot2-diagnostics-10-00288}

The magnetic sensors based on Faraday electromagnetic induction can also be used for magnetic LFIA reading. Briefly, the magnetic nanolabels are excited by an alternating magnetic field and, in turn, produce a stray magnetic field that is captured by a pick-up coil. Depending on the design, the signal is proportional to a change of self-inductance, impedance or resonance frequency of the pick-up coil. Different solutions are proposed that differ in the geometry and shape of the coils, the connection of several coils or combination of exciting frequencies \[[@B53-diagnostics-10-00288],[@B67-diagnostics-10-00288]\].

This technology allowed Barnett et al. \[[@B54-diagnostics-10-00288]\] to quantify prostate specific antigen (PSA) with a LOD of 0.8 ng/mL, and Nikitin et al. \[[@B55-diagnostics-10-00288]\] to quantify small molecules such as fluorescein, biotin and chloramphenicol. Orlov et al. \[[@B56-diagnostics-10-00288]\] extended the system to multiplex detection by the use of multiple pick-up coils wound around the different test lines; they simultaneously detected Botulinum Neurotoxins A, B and E in liquid samples with a LOD around 0.2 ng/mL. Among the commercial magnetic readers, the device of MagnaBioSciences (LLC, CA, USA) is most widely used in research articles, according to the number of papers \[[@B68-diagnostics-10-00288]\]. This desktop device excites the particles with a C-shaped magnet, and the signal is picked up by an array of thin-film coils. It has been used, for example, for reading out LFIA for quantification of tumour markers or pathogens \[[@B57-diagnostics-10-00288],[@B58-diagnostics-10-00288],[@B59-diagnostics-10-00288],[@B60-diagnostics-10-00288],[@B61-diagnostics-10-00288]\]. Gas et al. \[[@B63-diagnostics-10-00288]\] have used Magnisense portable device \[[@B62-diagnostics-10-00288]\] for quantification of marine toxic algae with LOD of $5 \times 10^{4}$ cells/mL.

Our group has developed a portable inductive sensor that scans the LFIA strip and measures the change of impedance produced by the initial magnetic permeability of the particles at radio frequency ([Figure 7](#diagnostics-10-00288-f007){ref-type="fig"}). In particles below the critical volume for superparamagnetic behaviour, the thermal energy has an enormous influence on the magnetization orientation. At radio frequencies, these nanoparticles are magnetically very susceptible, which can be used for their inductive detection, even without any externally applied field \[[@B69-diagnostics-10-00288],[@B70-diagnostics-10-00288]\]. This fact reduces the complexity and size of the overall device. Mechanical positioning is done by a PLA 3D-printed micro-positioner to avoid the use of any metallic moving parts that may induce artefacts in the measurement. We have applied this technique to the quantification of PSA in the clinical range of interest \[[@B64-diagnostics-10-00288]\] and histamine directly in red wine \[[@B65-diagnostics-10-00288]\].

4. Fields of Application {#sec4-diagnostics-10-00288}
========================

4.1. Conventional Magnetic LFIA for Analyte Detection {#sec4dot1-diagnostics-10-00288}
-----------------------------------------------------

Magnetic LFIAs have been used extensively in different fields: biomedicine, food, environmental control and drug monitoring. Regarding the agri-food sector, pathogen microorganisms (bacteria and virus), toxins and other hazardous molecules have been controlled and detected by magnetic LFIAs. For clinical analysis, proteins, cells and nucleic acids have been used in order to detect biomarkers, as well as hormones. In addition, the monitoring of drugs such as cocaine has been performed by means of LFIAs employing magnetic nanoparticles as labels. [Table 3](#diagnostics-10-00288-t003){ref-type="table"} and [Table 4](#diagnostics-10-00288-t004){ref-type="table"} summarize the latest magnetic LFIA reported with optical and magnetic detection, respectively.

Sandwich and competitive LFIAs are the most common formats. [Table 3](#diagnostics-10-00288-t003){ref-type="table"}, [Table 4](#diagnostics-10-00288-t004){ref-type="table"} and [Table 5](#diagnostics-10-00288-t005){ref-type="table"} show several competitive LFIA for detection of molecules of interest in different fields: melamine \[[@B72-diagnostics-10-00288]\], furazolidone metabolite of 3-amino-2-oxazolidinone (AOZ) \[[@B40-diagnostics-10-00288]\], cocaine \[[@B39-diagnostics-10-00288]\], histamine \[[@B65-diagnostics-10-00288]\], thyroxine \[[@B79-diagnostics-10-00288]\], unconjugated estriol (uE~3~) \[[@B82-diagnostics-10-00288]\] and aflatoxin B~1~ (AFB~1~) \[[@B84-diagnostics-10-00288]\]. In all cases, the competitive assays have been developed for small molecules. However, sandwich format is more suitable for larger mean size analytes such as proteins, virus or bacteria. The limits of detection for both formats are comparable, which implies that this parameter is independent of immunoassay structure. Hwang et al. \[[@B30-diagnostics-10-00288]\] have reported a magnetic LFIA based on unconventional format. The test line was formed by pressing the nitrocellulose membrane to decrease its thickness instead of immobilizing specific antibodies against bacteria, as it is done at the conventional procedure. The free gold/magnetic nanoparticles passed through the pore until they reached the pressed test line. However, *Salmonella*--gold/magnetic nanoparticles complexes remained in the solution because they were too large to flow along the membrane. The flow of free gold/magnetic nanoparticles was blocked at the test line displaying the colour on spot, which was inversely proportional to the bacteria concentration.

The limit of detection reported for both systems, optical and magnetic, are similar, thus there are not significant differences when comparing similar type of analytes. However, the possibilities for MNPs combined with preconcentration steps have not yet been fully explored. The detection ranges for bacteria obtained are from 10^3^ to 10^5^ CFU/mL. For virus, it was possible to quantify levels as low as ng/mL \[[@B71-diagnostics-10-00288]\] getting optical enhancement by means of double strategy based on (i) aggregation of magnetic nanoparticles with gold nanoparticles by biotin-streptavidin interactions, and (ii) pre-concentration with a magnetic field \[[@B25-diagnostics-10-00288]\]. The detectable concentration for other analytes is also in the nanogram per mL range for both optical and magnetic detection, although in some case concentrations lower than nanograms have been reached for magnetic-LFIA \[[@B36-diagnostics-10-00288],[@B80-diagnostics-10-00288]\].

It is worth remarking that gold-magnetic nanoparticles have been reported widely as alternative nanocomposite. Their use does not affect negatively to the limit of detection and they combine optical and magnetic transduction with an easy conjugation to biomolecules. In addition, they can be used for IMS.

Regarding the crystal structure of magnetic nanoparticles, magnetite (Fe~3~O~4~) has been the preferred option in order to develop LFIA. Li et al. \[[@B83-diagnostics-10-00288]\] have used MnFe~2~O~4~ instead of magnetite in order to achieve stronger magnetization. They hypothesized that the hybridization of iron and manganese atoms increased the spin magnetic moment between them, resulting in a higher total magnetic moment for the nanoparticle. Carboxyl groups on the MNP surface are the preferred functional groups for the development of LFIA, as shown in [Table 3](#diagnostics-10-00288-t003){ref-type="table"}, [Table 4](#diagnostics-10-00288-t004){ref-type="table"} and [Table 5](#diagnostics-10-00288-t005){ref-type="table"}.

4.2. Immunomagnetic Separation in Combination with Other Transduction Systems {#sec4dot2-diagnostics-10-00288}
-----------------------------------------------------------------------------

[Table 3](#diagnostics-10-00288-t003){ref-type="table"} and [Table 4](#diagnostics-10-00288-t004){ref-type="table"} show that magnetic nanoparticles have mainly been used as reporters, but they can also be used for IMS, which would lower the limit of detection in comparison with a standard LFIA. A strategy to preconcentrate the analyte from matrix or/and locate it in the detection zone (test line for LFIA) with an external magnetic field has been reported, showing the capacity to decrease the lowest detectable concentration \[[@B78-diagnostics-10-00288]\]. In some applications, magnetic nanoparticles have been used to perform a double function simultaneously: separation and label for optical detection \[[@B25-diagnostics-10-00288],[@B35-diagnostics-10-00288],[@B78-diagnostics-10-00288]\]. In other cases, gold and fluorescent nanoparticles have been employed in combination with magnetic nanoparticles in order to use optical nanoparticles for the transduction and magnetic nanoparticles for the IMS \[[@B85-diagnostics-10-00288],[@B88-diagnostics-10-00288],[@B89-diagnostics-10-00288]\]. Nanocomposites combining magnetic nanoparticles with gold or fluorescent nanomaterials have also been reported to get the same double function \[[@B84-diagnostics-10-00288],[@B87-diagnostics-10-00288]\]. This approach has enabled the detection of 10^0^ CFU/mL for bacteria \[[@B24-diagnostics-10-00288]\] and biomarkers in picogram range \[[@B36-diagnostics-10-00288],[@B84-diagnostics-10-00288]\].

MNP have been used for IMS in combination with other detection systems to improve sensitivity (visual, electrochemical and fluorescent), as shown in [Table 5](#diagnostics-10-00288-t005){ref-type="table"}. Poonlapdecha et al. \[[@B24-diagnostics-10-00288]\] preconcentrated *Campylobacter jejuni* present in poultry samples by IMS for subsequent DNA extraction and nucleic acid detection by LFIA. Li et al. \[[@B85-diagnostics-10-00288]\] employed a similar procedure for detection of *Listeria monocytogenes* in lettuce samples. In addition, IMS as previous pretreatment to fluorescent LFI was employed to detect *Listeria monocytogenes* \[[@B89-diagnostics-10-00288]\]. Nanocomposites containing magnetic and fluorescent nanoparticles were developed to combine IMS with fluorescence detection of toxins \[[@B84-diagnostics-10-00288]\]. IMS combined with colloidal gold-based LFIA for detection of *Enterobacter cloacae* enhanced the sensitivity in comparison with conventional LFIA \[[@B88-diagnostics-10-00288]\]. Other strategy that combine gold nanoparticles based LFIA with magnetic gold nanostructure for bacteria detection was developed \[[@B87-diagnostics-10-00288]\]. In this case, magnetic nanostructures were used to locate the analyte at the detection zone by means of external magnet, in order to increase the reaction time for the immunoassay. The authors have also employed enzymes conjugated to gold nanoparticles to enable an extra-colour change and enhance the sensitivity.

Electrochemical transductions have been reported coupled to magnetic LFIA by means of personal blood glucose meters, which are widely used as point of care devices for people with diabetes. *Escherichia coli* was quantified by using these personal glucometers \[[@B86-diagnostics-10-00288]\]. The strategy is based on the use of magnetic nanoparticles attached to invertase and antibodies against *E. coli* in order to carry out both electrochemical transduction and IMS. A different approach using these devices to quantify a biomarker of gamma-radiation exposure has recently been reported \[[@B90-diagnostics-10-00288]\]. In this case, magnetic nanoparticles functionalized with specific antibodies have been used to locate the analyte in the test line with the help of a magnet. Then glucose-encapsulating liposomes were used as labels for electrochemical detection. The limit of detection obtained by personal glucose meters ([Table 5](#diagnostics-10-00288-t005){ref-type="table"}) are comparable with other detection methods described previously.

[Table 6](#diagnostics-10-00288-t006){ref-type="table"} shows the limit of detection improvements by combining the detection principle with IMS.

5. Conclusions {#sec5-diagnostics-10-00288}
==============

The development of LFIAs using magnetic nanoparticles has emerged as a research field of great interest in the past five years. Magnetic-LFIA would enable POCT instruments to detect biomarkers, pathogens, toxins, allergens and drugs. At present, there are different magnetic transducers under research that could be coupled to LFIA. Some commercial readers, based on magnetic and optical transduction, are also available.

The control on the properties of the nanoparticles used is crucial for the development of the applications. Gold-magnetic core-shell nanoparticles have been employed as alternative to conventional nanoparticles in order to combine the properties of both materials. Nanocomposites with both materials have attracted a lot of interest to combine both the superparamagnetism of Fe~3~O~4~ and the surface chemistry of Au component. This enables an easy functionalization in addition to a simple separation. Although MNP are mainly used as labels, they can be employed for IMS as well, either as a previous step to LFIA or to concentrate the analyte at the detection zone. The most common functional group use to functionalize MNP is carboxyl group, which allows an easy conjugation to biomolecules with amine groups by carbodiimide chemistry. The magnetic nanoparticles sizes reported vary from 10 nm to 400 nm and magnetite has been the most employed crystalline structure.

The analysis of the literature reported in this review indicates that magnetic LFIAs with quantitative capability are a suitable alternative to develop quantitative biosensors for a wide range of applications.

Some figures were created using [BioRender.com](BioRender.com).
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![Summary of the basic formats of lateral flow assays. (**A**) Scheme of a sandwich format lateral flow immunoassays (LFIA). (**B**) Scheme of a competitive format LFIA: (1) when antigen is immobilized at the test line and labelled antibody is used as detection system; (2) when antibody is immobilized at the test line and labelled antigen is used for detection.](diagnostics-10-00288-g001){#diagnostics-10-00288-f001}

![Scheme of the immunomagnetic separation (IMS) procedure.](diagnostics-10-00288-g002){#diagnostics-10-00288-f002}

![Transmission electron microscopy images of magnetite nanoparticles. (**A**) Monodisperse MNP with spherical shape and (**B**) polydisperse nanoparticles with irregular spherical shape.](diagnostics-10-00288-g003){#diagnostics-10-00288-f003}

![Schematic representation of direct bond between gold\@magnetic nanoparticles and proteins (**A**), covalent bond between gold\@magnetic nanoparticles and proteins (**B**) and covalent bond between functionalized magnetic nanoparticles and proteins (**C**).](diagnostics-10-00288-g004){#diagnostics-10-00288-f004}

![Detection of magnetic nanoparticles used as labels in LFIA: (**A**) visual detection by naked eye. (**B**) Optical detection using smartphone with special software. (**C**) Magnetic quantification using magnetic transduction. (**D**) Advantages of magnetic detection over optical detection.](diagnostics-10-00288-g005){#diagnostics-10-00288-f005}

![(**A**) Schemes of a Giant Magnetoresistance (GMR) sensor (left), and a Tunnel Magnetoresistance (TMR) sensor (right). (**B**) Scheme of the resistance of the MR sensor as a function of the applied field (black line). The MNP's magnetic moments align in the direction of the applied field, and their solenoidal magnetostatic field reduces the magnetization of the free layer (the magnetic field lines are represented as grey dashed lines.) In consequence, if the applied field is positive, the resistance of the sensor decreases, and if it is negative, the resistance increases (red line).](diagnostics-10-00288-g006){#diagnostics-10-00288-f006}

![**Left**: Scheme of the scanning inductive reader for magnetic LFIA. **Right**: Signal recorded for histamine competitive LFIA (blank sample, competitive immunoassay).](diagnostics-10-00288-g007){#diagnostics-10-00288-f007}

diagnostics-10-00288-t001_Table 1

###### 

Characterization techniques and their corresponding information obtained for magnetic nanoparticles (MNPs).

  Techniques                                                                                Characterization Information
  ----------------------------------------------------------------------------------------- --------------------------------------------------------------
  Microscopy: Transmission electron microscopy and Scanning electron microscopy             Morphology, size distribution, crystallinity and composition
  X-ray diffraction (XRD)                                                                   Crystal structure and size
  Dynamic light scattering (DLS)                                                            Hydrodynamic size
  Infrared spectroscopy (IR)                                                                Nature of surface and functional groups on surface
  Zeta potential                                                                            Surface charge and stability
  Thermal analysis                                                                          Concentration and thermal stability
  Mass spectroscopy                                                                         Concentration
  Superconducting quantum interference device (SQUID)/Vibrating sample magnetometry (VSM)   Magnetic properties
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###### 

Type of magnetic nanoparticles used for each magnetic transducing principle.

  Transducing Principle                                                   Nanoparticles                                                           References
  ----------------------------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------
  **Magnetoresistive LFIA readers**                                       Superparamagnetic nanoparticles                                         \[[@B45-diagnostics-10-00288]\]
  Superparamagnetic maghemite nanoparticles                               \[[@B46-diagnostics-10-00288]\]                                         
  Beads of 440 nm in diameter                                             \[[@B47-diagnostics-10-00288]\]                                         
  Superparamagnetic Maghemite nanoparticles (200 nm)                      \[[@B48-diagnostics-10-00288]\]                                         
  Magnetic beads of 200 nm                                                \[[@B49-diagnostics-10-00288]\]                                         
  Superparamagnetic nanoparticles (10.5 nm)                               \[[@B50-diagnostics-10-00288]\]                                         
  \[[@B51-diagnostics-10-00288]\]                                                                                                                 
  Superparamagnetic nanoparticles (80 nm)                                 \[[@B52-diagnostics-10-00288]\]                                         
  **Inductive LFIA readers**                                              Superparamagnetic nanoparticles encapsulated in microspheres (198 nm)   \[[@B53-diagnostics-10-00288]\]
  Paramagnetic particles (760 nm)                                         \[[@B54-diagnostics-10-00288]\]                                         
  Superparamagnetic nanoparticles (50 nm)                                 \[[@B55-diagnostics-10-00288]\]                                         
  Superparamagnetic nanoparticles encapsulated in microspheres (198 nm)   \[[@B56-diagnostics-10-00288]\]                                         
  Magnetic nanobeads (15, 80 and 200 nm)                                  \[[@B57-diagnostics-10-00288]\]                                         
  Superparamagnetic nanoparticles (140 nm)                                \[[@B58-diagnostics-10-00288]\]                                         
  Superparamagnetic nanoparticles (15 nm)                                 \[[@B59-diagnostics-10-00288]\]                                         
  Superparamagnetic nanoparticles (140 nm)                                \[[@B60-diagnostics-10-00288]\]                                         
  Colorimetric-Fluorescent-Magnetic nanospheres (300 nm)                  \[[@B61-diagnostics-10-00288]\]                                         
  Superparamagnetic nanoparticles (10 nm)                                 \[[@B62-diagnostics-10-00288]\]                                         
  Superparamagnetic nanoparticles (200 nm)                                \[[@B63-diagnostics-10-00288]\]                                         
  Superparamagnetic nanoparticles (10.5 nm)                               \[[@B64-diagnostics-10-00288]\]                                         
  Superparamagnetic magnetite nanoparticles                               \[[@B65-diagnostics-10-00288]\]                                         
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###### 

Most recent Magnetic LFIA with optical detection.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nanoparticles                 Conjugation                                                 Detection                                                        Analyte                                                    Limit of Detection          Reference
  ----------------------------- ----------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------- --------------------------- ---------------------------------
  **Pathogens**                                                                                                                                                                                                                                     

  Gold magnetic nanoparticles   Via Au--S bonds                                             Visual detection                                                 *Salmonella choleraesuis*                                  5 × 10^5^ CFU/mL            \[[@B37-diagnostics-10-00288]\]

  Gold magnetic nanoparticles   Via Au--S bonds                                             Colour intensity. ImageJ density analysis                        *Salmonella*                                               10^3^ CFU/mL                \[[@B30-diagnostics-10-00288]\]

  Magnetic nanoparticles        EDC/NHS Chemistry                                           Colour intensity. TotalLab TL120                                 Potato virus X                                             0.5 ng/mL                   \[[@B71-diagnostics-10-00288]\]

  Magnetic nanoparticles        EDC/NHS Chemistry                                           Colour intensity. TotalLab TL120                                 Potato virus X                                             0.25 ng/mL                  \[[@B25-diagnostics-10-00288]\]

  Gold magnetic nanoparticles   Via Au--S bonds                                             Visual detection                                                 Avian influenza virus subtype H7 (AIV H7)                  10^3^ ^5^ EID~50~           \[[@B33-diagnostics-10-00288]\]

  **Toxins and allergens**                                                                                                                                                                                                                          

  Gold magnetic nanoparticles   Via Au--S bonds                                             Visual detection                                                 β-Conglutin                                                8 fM                        \[[@B35-diagnostics-10-00288]\]

  Magnetic nanoparticles        EDC/NHS Chemistry                                           Visual detection                                                 Melamine                                                   0.4 ppm for Fe~2~O~3~PEG\   \[[@B72-diagnostics-10-00288]\]
                                                                                                                                                                                                                        2.2 ppm for Fe~3~O~4~-PEG   

  Magnetic nanoparticles        EDC/NHS Chemistry                                           Visual detection                                                 Furazolidone metabolite of 3-amino-2-oxazolidinone (AOZ)   0.044 ng/mL                 \[[@B40-diagnostics-10-00288]\]

  **Biomarkers**                                                                                                                                                                                                                                    

  Magnetic nanoparticles        EDC chemistry                                               Visual detection                                                 Carcinoembryonic antigen (CEA)                             0.25 ng/mL                  \[[@B73-diagnostics-10-00288]\]

  Magnetic nanoparticles        EDC/NHS Chemistry                                           Reflectance measurements. ESE Quant LR3 (Qiagen Inc., Germany)   Extracellular vesicles (EVs)                               10^7^ EVs/mL                \[[@B74-diagnostics-10-00288]\]

  Gold magnetic nanoparticles   EDC chemistry                                               Visual detection                                                 Genotyping of MTHFR C677T                                  5 ng                        \[[@B75-diagnostics-10-00288]\]

  Gold magnetic nanoparticles   CTAB-PSS modification (direct bonds)                        Visual detection                                                 Genotype Apolipoprotein E                                  10 ng                       \[[@B76-diagnostics-10-00288]\]

  Gold magnetic nanoparticles   EDC chemistry                                               Visual detection                                                 IgM class antibodies related infections                    \-                          \[[@B77-diagnostics-10-00288]\]

  Magnetic nanoparticles        Periodate-based oxidation of the glycosylated Fc residues   Colour intensity. ImageJ density analysis                        Human chorionic gonadotropin (hCG)                         0.31 ng/mL                  \[[@B78-diagnostics-10-00288]\]

  **Drugs**                                                                                                                                                                                                                                         

  Magnetic nanoparticles        EDC/NHS Chemistry                                           Smart phone camera was used for quantitative analysis            Cocaine                                                    5 ng/mL                     \[[@B39-diagnostics-10-00288]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Most recent Magnetic LFIA with magnetic detection.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nanoparticles                                     Conjugation         Detection                                                        Analyte                                          Limit of Detection                                        Reference
  ------------------------------------------------- ------------------- ---------------------------------------------------------------- ------------------------------------------------ --------------------------------------------------------- ---------------------------------
  **Pathogens**                                                                                                                                                                                                                                     

  Magnetic nanoparticles                            EDC/NHS Chemistry   MAR system (MagnaBioSciences, CA, USA)                           *Vibrio parahaemolyticus*                        4.73 × 10^3^ CFU/mL                                       \[[@B60-diagnostics-10-00288]\]

  Colorimetric-Fluorescent-Magnetic nanoparticles   EDC/NHS Chemistry   MAR system (MagnaBioSciences, CA, USA)\                          *Salmonella typhimurium*                         1.88 × 10^4^ CFU/mL: naked detection\                     \[[@B61-diagnostics-10-00288]\]
                                                                        Fibre optic spectrometer                                                                                          3.75 × 10^3^ CFU/mL: magnetic and fluorescent detection   

  Magnetic nanoparticles                            EDC/NHS Chemistry   Reader Miateks (Magnisense)                                      *Alexandrium minutum*                            10^5^ cells/L                                             \[[@B63-diagnostics-10-00288]\]

  **Toxins and allergens**                                                                                                                                                                                                                          

  Magnetic nanoparticles                            EDC/NHS Chemistry   Magnetic particle quantification (MPQ) method                    Botulinum neurotoxin (BoNT) types A, B and E     0.22 ng/mL for BoNT-A\                                    \[[@B56-diagnostics-10-00288]\]
                                                                                                                                                                                          0.11 ng/mL for BoNT-B\                                    
                                                                                                                                                                                          0.32 ng/mL for BoNT-E                                     

  Magnetic nanoparticles                            EDC/NHS Chemistry   Novel sensor developed by authors\                               Histamine                                        1.2 mg/L for magnetic sensor\                             \[[@B65-diagnostics-10-00288]\]
                                                                        Reflectance measurements. ESE Quant LR3 (Qiagen Inc., Germany)                                                    1.5 mg/L for optical reader                               

  **Biomarkers**                                                                                                                                                                                                                                    

  Magnetic nanoparticles                            EDC/NHS Chemistry   MAR system (MagnaBioSciences, CA, USA)                           Carbohydrate antigen 72-4 (CA72-4)               0.38 IU/mL                                                \[[@B59-diagnostics-10-00288]\]

  Magnetic nanoparticles                            EDC/NHS Chemistry   Novel sensor developed by authors\                               Prostate-Specific Antigen                        0.25 ng/mL                                                \[[@B64-diagnostics-10-00288]\]
                                                                        Reflectance measurements. ESE Quant LR3 (Qiagen Inc., Germany)                                                                                                              

  Magnetic nanoparticles                            EDC/NHS Chemistry   MAR system (MagnaBioSciences, CA, USA)                           Neuron specific enolase (NSE)\                   0.094 ng/mL for NSE 0.045 ng/mL for CEA                   \[[@B57-diagnostics-10-00288]\]
                                                                                                                                         carcinoembryonic antigen (CEA).                                                                            

  Magnetic nanoparticles                            EDC/NHS Chemistry   Magnetic particle quantification (MPQ) method                    Thyroxine                                        20 fM                                                     \[[@B79-diagnostics-10-00288]\]

  Magnetic nanoparticles                            EDC Chemistry       MAR system (MagnaBioSciences, CA, USA)                           Amino-terminal pro-B-type natriuretic peptide\   100 pg/mL                                                 \[[@B80-diagnostics-10-00288]\]
                                                                                                                                         (NT-proBNP)                                                                                                

  Gold magnetic nanoparticles                       EDC Chemistry       MAR system (MagnaBioSciences, CA, USA)                           Single nucleotide polymorphisms (SNPs)           0.04 pg/μL with plasmid                                   \[[@B36-diagnostics-10-00288]\]

  Magnetic nanoparticles                            EDC/NHS Chemistry   MIR system developed by authors                                  Troponin I (cTnI)\                               0.0089 ng/mL for cTnI\                                    \[[@B81-diagnostics-10-00288]\]
                                                                                                                                         Creatine kinase isoenzyme MB (CKMB)\             0.063 ng/mL for CKMB\                                     
                                                                                                                                         Myoglobin (Myo)                                  0.05 ng/mL for Myo                                        

  Magnetic nanoparticles                            EDC/NHS Chemistry   MAR system (MagnaBioSciences, CA, USA)                           Unconjugated estriol (uE3)                       0.86 nmol/L                                               \[[@B82-diagnostics-10-00288]\]

  Magnetic nanoparticles                            EDC/NHS Chemistry   MAR system (MagnaBioSciences, CA, USA)                           D-dimer                                          0.05 μg/mL                                                \[[@B83-diagnostics-10-00288]\]

  Gold magnetic nanoparticles                       \-                  Magnetic quantitative immunoanalyzer                             C-reactive protein (CRP)                         0.15 mg/mL                                                \[[@B34-diagnostics-10-00288]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Other detection and magnetic nanoparticles used for immunomagnetic separation.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nanoparticles                        Conjugation                    Detection                                                                                                       Analyte                                                   Limit of Detection                  Reference
  ------------------------------------ ------------------------------ --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ----------------------------------- ---------------------------------
  Magnetic nanoparticles               Glutaraldehyde chemistry       Visual detection                                                                                                *Campylobacter jejuni*                                    10^0^ with pure culture\            \[[@B24-diagnostics-10-00288]\]
                                                                                                                                                                                                                                                10^1^ with poultry samples          

  Magnetic nanoparticles               Biotin-streptavidin affinity   Visual detection                                                                                                *Listeria monocytogenes*                                  3.5 × 10^3^ CFU/mL for standards\   \[[@B85-diagnostics-10-00288]\]
                                                                                                                                                                                                                                                3.5 × 10^4^ CFU/g in real samples   

  Magnetic nanoparticles               EDC/NHS Chemistry              Electrochemical detection.\                                                                                     *Escherichia coli O157:H7*                                6.2 × 10^4^ CFU/mL                  \[[@B86-diagnostics-10-00288]\]
                                                                      Glucose meter                                                                                                                                                                                                 

  Gold magnetic nanoparticles          Via Au--S bonds                Visual detection                                                                                                *Escherichia coli O157:H7* and *Salmonella typhimurium*   23 CFU/mL for E. coli\              \[[@B87-diagnostics-10-00288]\]
                                                                                                                                                                                                                                                17 CFU/mL for Salmonella            

  Magnetic nanoparticles               Glutaraldehyde chemistry       Visual detection.                                                                                               *Enterobacter cloacae*                                    10^2^ CFU/mL                        \[[@B88-diagnostics-10-00288]\]

  Magnetic nanoparticles               EDC/NHS Chemistry              Fluorescent detection                                                                                           *Listeria monocytogenes*                                  10^4^ CFU/mL                        \[[@B89-diagnostics-10-00288]\]

  Fluorescent magnetic nanoparticles   EDC chemistry                  Fluorescent detection. Fluorescent strip reader (Suzhou Hemai Precision Instrument Co., Ltd. Jiangsu, China).   Aflatoxin B~1~ (AFB~1~)                                   3 pg/mL in sauce extract\           \[[@B84-diagnostics-10-00288]\]
                                                                                                                                                                                                                                                51 pg/mL in real dark soy sauce     

  Magnetic nanoparticles               EDC/NHS Chemistry              Electrochemical detection.\                                                                                     Phospho-p53^15^                                           50 pg/mL                            \[[@B90-diagnostics-10-00288]\]
                                                                      Glucose meter                                                                                                                                                                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Limit of detection improvements using IMS.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Analyte                                          Limit of Detection Using LFIA                                                  Limit of Detection Using LFIA in Combination with IMS   References
  ------------------------------------------------ ------------------------------------------------------------------------------ ------------------------------------------------------- -----------------------------------------------------------------------------------------
  **Gold nanoparticles as label**                                                                                                                                                         

  *Campylobacter jejuni*                           10^5^ cfu/mL for gold nanoparticles (pure culture)\                            10^0^ cfu/mL (pure culture)\                            \[[@B24-diagnostics-10-00288],[@B91-diagnostics-10-00288],[@B92-diagnostics-10-00288]\]
                                                   10^4^ cfu/mL for quantum dots (pure culture)                                   10^1^ cfu/mL (poultry sample)                           

  *Listeria monocytogenes*                         10^4^ cfu/mL for superparamagnetic nanoparticles\                              3.5 × 10^3^ cfu/mL (buffer)\                            \[[@B58-diagnostics-10-00288],[@B85-diagnostics-10-00288],[@B93-diagnostics-10-00288]\]
                                                   3.7 × 10^6^ cfu/mL for gold nanoparticles                                      3.5 × 10^4^ cfu/g (lettuce samples)                     

  *E. coli O157:H7* and *Salmonella typhimurium*   *E. coli O157:H7*\                                                             23 CFU/mL for *E. coli*\                                \[[@B87-diagnostics-10-00288],[@B94-diagnostics-10-00288],[@B95-diagnostics-10-00288]\]
                                                   10^5^ cfu/mL for gold nanoparticles\                                           17 CFU/mL for *Salmonella*                              
                                                   10^4^ cfu/mL for fluorescent microspheres\                                                                                             
                                                   *Salmonella typhimurium*\                                                                                                              
                                                   10^4^ cfu/mL for gold nanoparticles                                                                                                    

  *Potato virus X*                                 0.25 ng/mL for combination of magnetic nanoparticles with gold nanoparticles   8 ng/mL                                                 \[[@B25-diagnostics-10-00288]\]

  *Enterobacter cloacae*                           10^3^ cfu/mL for gold nanoparticles                                            10^2^ cfu/mL                                            \[[@B88-diagnostics-10-00288]\]

  β-conglutin                                      5 nM for gold nanoparticles                                                    8 fM                                                    \[[@B35-diagnostics-10-00288]\]

  **Fluorescent nanoparticles**                                                                                                                                                           

  Aflatoxin B1                                     10 µg/mL for gold nanoparticles\                                               3 pg/mL in sauce extract\                               \[[@B84-diagnostics-10-00288],[@B96-diagnostics-10-00288],[@B97-diagnostics-10-00288]\]
                                                   0.1 ng/mL for silver\@gold nanoparticles                                       51 pg/mL in real dark soy sauce                         

  *Listeria monocytogenes*                         3.7 × 10^6^ cfu/mL for gold nanoparticles                                      10^4^ CFU/mL                                            \[[@B89-diagnostics-10-00288],[@B93-diagnostics-10-00288]\]

  **Electrochemical detection**                                                                                                                                                           

  *Escherichia coli O157:H7*                       10^5^ cfu/mL for gold nanoparticles\                                           6.2 × 10^4^ CFU/mL                                      \[[@B86-diagnostics-10-00288],[@B95-diagnostics-10-00288]\]
                                                   10^4^ cfu/mL for fluorescent microspheres                                                                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
